CVD AND TYPE 2 DIABETES: NAVIGATING THERAPEUTIC BOUNDARIES IN GLP-1 RA USE
This content is not intended for UK or US HCPs.
The purpose of this programme, 'CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use', is to equip cardiologists with the most up-to-date clinical data to facilitate the adoption of GLP-1 RAs. The programme will provide comprehensive education on the current issues related to CVD and GLP-1 RA treatment, ensuring appropriate implementation of guideline recommendations and creating a shift towards the optimal use of these agents as part of routine CV care.
Prof Tina Vilsbøll (Steno Diabetes Centre, Copenhagen, DK) leads proceedings, and is joined by Dr John Buse (University of North Carolina, School of Medicine, Chapel Hill, US), Dr Neha Pagidipati (Duke Clinical Research Institute, Durham, US), and Dr Linda G Mellbin (Karolinska Institute, Stockholm, SE) for insightful presentations and engaging discussions.
This programme is intended to educate:
The overall programme, 'CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1RA Use', endeavours to best address the following learning objectives:
- Describe the burden of ASCVD in type 2 diabetes
- Assign risk of future CV events to individuals with type 2 diabetes
- Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
- Recall trial data of anti-diabetes medications that reduce ASCVD risk
- Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
- Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
- Adopt anti-diabetic therapies with proven ASCVD benefit
This programme is created by Radcliffe Medical Education and Supported by an unrestricted educational grant by Novo Nordisk A/S.
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. This programme is created by Radcliffe Medical Education and Supported by an unrestricted educational grant by Novo Nordisk A/S.
R-CME DISCLAIMER / TERMS & CONDITIONS
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, 'CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use' is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 2 hours of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
INSTRUCTIONS TO PARTICIPANTS
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 120 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
MACE in T2D: Which Patients Are High Risk?
Optimal Approach To Establishing Risk - Dr Linda G. Mellbin
The Complex Relationship Between ASCVD & T2D - Prof Tina Vilsbøll
CVD Risk Classification: How Can It Be Better? CV Perspective - Dr Linda G. Mellbin
CVD Risk Classification: How Can It Be Better? Endo perspective - Prof Tina Vilsbøll
Addressing High CVD Risk: A Patient-tailored Approach
Antihyperglycemics: The Key Players in CV Outcomes - Dr John Buse
A Deep Dive Into HF & Renal Outcomes - Dr Linda G. Mellbin
A Deep Dive Into ASCVD Outcomes - Dr Linda G. Mellbin
Optimising Therapy in High-risk Patients
T2D: Tackling Early & Hard - Prof Tina Vilsbøll
QOL: A Holistic View of GLP-1 RAs - Dr Neha Pagidipati
Practical Use of GLP-1 RAs: An Everyday Guide
Guidance For GLP-1 RAs in CAD: How The Approach Is Changing - Dr John Buse
GLP-1 RAs: Implementation in Real World Practice - Dr Neha Pagidipati
Multidisciplinary Care of High-risk T2D: How Everyone Can Play a Part
Identifying High-risk: How To Stop Patients Slipping Through the Net
GLP-1 RA Therapy: Getting Started & Staying on Track
The MDT: Assembling the Best Care
Prof Tina Vilsbøll - Steno Diabetes Centre, Copenhagen, DK
Dr John Buse - University of North Carolina, School of Medicine, Chapel Hill, US
Dr Neha Pagidipati - Duke Clinical Research Institute, Durham, US
Dr Linda G Mellbin - Karolinska Institute, Stockholm, SE
- 2.00 European Board for Accreditation in Cardiology (EBAC)